{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:19:30Z","timestamp":1787685570442,"version":"build-2784847793"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"BIH clinician scientist Charite program"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Bispecific T cell engagers (TCE) targeting BCMA or GPRC5D have improved outcomes in relapsed\/refractory multiple myeloma (MM), yet up to 40% of patients are primarily refractory, and predictive biomarkers are scarce. To address this unmet clinical need, we developed an image-based, high-content ex vivo assay using patient-derived bone marrow mononuclear cells exposed to teclistamab or talquetamab. Multiplex immunofluorescence enabled single-cell quantification of plasma cell lysis, T cell expansion, T cell morphology, and spatial T cell\u2013plasma cell engagement. Across all ex vivo\n                    <jats:italic>-<\/jats:italic>\n                    treated patient samples, we identified three functional response phenotypes: non-responder, cytotoxic, and cytotoxic-expansive. Based on this classification, we delineated a morphologic T cell activation trajectory from resting to polarized and effector states. Progression along this trajectory reflected ex vivo plasma cell killing efficacy and distinguished productive from abortive immunological synapses. Importantly, ex vivo response phenotypes stratified clinical response and time on therapy in patients receiving TCE monotherapy, positioning image-based ex vivo profiling as a functional biomarker for immune competence and therapy stratification in MM.\n                  <\/jats:p>","DOI":"10.1038\/s41375-026-03047-5","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:06:42Z","timestamp":1784207202000},"page":"1997-2007","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy"],"prefix":"10.1038","volume":"40","author":[{"given":"Frederik","family":"Herzberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4782-9436","authenticated-orcid":false,"given":"Feiteng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2988-8483","authenticated-orcid":false,"given":"Michael","family":"Korenkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Fregona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carin","family":"Didoss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Heisterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Sprechert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Polici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Heck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4649-0506","authenticated-orcid":false,"given":"Jan","family":"Kr\u00f6nke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8485-1958","authenticated-orcid":false,"given":"Ulrich","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9379-3342","authenticated-orcid":false,"given":"Stephan R.","family":"Bohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"3047_CR1","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"3047_CR2","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3047_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, Van De Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"3047_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, Van De Donk NWCJ, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344.","journal-title":"N Engl J Med"},{"key":"3047_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29:2259\u201367.","journal-title":"Nat Med"},{"key":"3047_CR6","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"K Pillarisetti","year":"2020","unstructured":"Pillarisetti K, Powers G, Luistro L, Babich A, Baldwin E, Li Y, et al. Teclistamab is an active T cell\u2013redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020;4:4538\u201349.","journal-title":"Blood Adv"},{"key":"3047_CR7","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41573-024-00896-6","volume":"23","author":"C Klein","year":"2024","unstructured":"Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov. 2024;23:301\u201319.","journal-title":"Nat Rev Drug Discov"},{"key":"3047_CR8","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","volume":"41","author":"P Moreau","year":"2024","unstructured":"Moreau P, Mateos MV, Gonzalez Garcia ME, Einsele H, De Stefano V, Karlin L, et al. Comparative effectiveness of teclistamab versus real-world physicians\u2019 choice of therapy in locomotion and moment in triple-class exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:696\u2013715.","journal-title":"Adv Ther"},{"key":"3047_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"C Riedhammer","year":"2024","unstructured":"Riedhammer C, Bassermann F, Besemer B, Bewarder M, Brunner F, Carpinteiro A, et al. Real-world analysis of teclistamab in 123 RRMM patients from Germany. Leukemia. 2024;38:365\u201371.","journal-title":"Leukemia"},{"key":"3047_CR10","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1007\/s12325-024-02797-x","volume":"41","author":"H Einsele","year":"2024","unstructured":"Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, et al. Comparative efficacy of talquetamab vs. current treatments in the locommotion and momment studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma. Adv Ther. 2024;41:1576\u201393.","journal-title":"Adv Ther"},{"key":"3047_CR11","doi-asserted-by":"crossref","unstructured":"Frenking JH, Riedhammer C, Teipel R, Bassermann F, Besemer B, Bewarder M, et al. A German multicenter real-world analysis of talquetamab in 138 patients with relapsed\/refractory multiple myeloma. HemaSphere. 2025.","DOI":"10.1002\/hem3.70114"},{"key":"3047_CR12","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"D Cortes-Selva","year":"2024","unstructured":"Cortes-Selva D, Perova T, Skerget S, Vishwamitra D, Stein S, Boominathan R, et al. Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024;144:615\u201328.","journal-title":"Blood"},{"key":"3047_CR13","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1182\/blood.2024026212","volume":"144","author":"H Lee","year":"2024","unstructured":"Lee H, Durante M, Skerget S, Vishwamitra D, Benaoudia S, Ahn S, et al. Impact of soluble BCMA and non\u2013T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma. Blood. 2024;144:2637\u201351.","journal-title":"Blood"},{"key":"3047_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306.","journal-title":"Nat Med"},{"key":"3047_CR15","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/S2352-3026(24)00186-8","volume":"11","author":"NWCJ Van De Donk","year":"2024","unstructured":"Van De Donk NWCJ, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11:e693\u2013707.","journal-title":"Lancet Haematol"},{"key":"3047_CR16","doi-asserted-by":"crossref","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Bruins WSC, Duetz C, Kruyswijk S, et al. Impact of T-cell characteristics on response and resistance to T-cell redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res 2024;30:3006\u20133022.","DOI":"10.1158\/1078-0432.CCR-23-3333"},{"key":"3047_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","volume":"2","author":"EW Meermeier","year":"2021","unstructured":"Meermeier EW, Welsh SJ, Sharik ME, Du MT, Garbitt VM, Riggs DL, et al. Tumor burden limits bispecific antibody efficacy through T-cell exhaustion, averted by concurrent cytotoxic Therapy. Blood Cancer Discov. 2021;2:354\u201369.","journal-title":"Blood Cancer Discov"},{"key":"3047_CR18","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"MJ Friedrich","year":"2023","unstructured":"Friedrich MJ, Neri P, Kehl N, Michel J, Steiger S, Kilian M, et al. The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients. Cancer Cell. 2023;41:711\u2013725.e6.","journal-title":"Cancer Cell"},{"key":"3047_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40:26\u201335.","journal-title":"Cancer Cell"},{"key":"3047_CR20","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, et al. Image-based ex vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017;4:e595\u2013606.","journal-title":"Lancet Haematol"},{"key":"3047_CR21","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022;12:372\u201387.","journal-title":"Cancer Discov"},{"key":"3047_CR22","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/s41591-024-02848-4","volume":"30","author":"AM Acanda De La Rocha","year":"2024","unstructured":"Acanda De La Rocha AM, Berlow NE, Fader M, Coats ER, Saghira C, Espinal PS, et al. Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers. Nat Med. 2024;30:990\u20131000.","journal-title":"Nat Med"},{"key":"3047_CR23","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3:1416\u201329.","journal-title":"Cancer Discov"},{"key":"3047_CR24","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/s43018-023-00645-5","volume":"4","author":"N Liebers","year":"2023","unstructured":"Liebers N, Bruch PM, Terzer T, Hernandez-Hernandez M, Paramasivam N, Fitzgerald D, et al. Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial. Nat Cancer. 2023;4:1648\u201359.","journal-title":"Nat Cancer"},{"key":"3047_CR25","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/s43018-023-00544-9","volume":"4","author":"K Kropivsek","year":"2023","unstructured":"Kropivsek K, Kachel P, Goetze S, Wegmann R, Festl Y, Severin Y, et al. Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma. Nat Cancer. 2023;4:734\u201353.","journal-title":"Nat Cancer"},{"key":"3047_CR26","doi-asserted-by":"crossref","unstructured":"Severin Y, Hale BD, Mena J, Goslings D, Frey BM, Snijder B. Multiplexed high-throughput immune cell imaging reveals molecular health-associated phenotypes. Sci Adv. 2022;8:eabn5631.","DOI":"10.1126\/sciadv.abn5631"},{"key":"3047_CR27","doi-asserted-by":"crossref","unstructured":"Hale BD, Severin Y, Graebnitz F, Stark D, Guignard D, Mena J, et al. Cellular architecture shapes the na\u00efve T cell response. Science. 2024;7.","DOI":"10.1126\/science.adh8967"},{"key":"3047_CR28","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S1074-7613(00)80409-4","volume":"4","author":"PA Negulescu","year":"1996","unstructured":"Negulescu PA, Krasieva TB, Khan A, Kerschbaum HH, Cahalan MD. Polarity of T cell shape, motility, and sensitivity to antigen. Immunity. 1996;4:421\u201330.","journal-title":"Immunity"},{"key":"3047_CR29","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1878-0261.13191","volume":"16","author":"M Giliberto","year":"2022","unstructured":"Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Sk\u00e5nland SS, Gade A, Tj\u00f8nnfjord GE, et al. Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Mol Oncol. 2022;16:1241\u201358.","journal-title":"Mol Oncol"},{"key":"3047_CR30","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/nprot.2016.105","volume":"11","author":"MA Bray","year":"2016","unstructured":"Bray MA, Singh S, Han H, Davis CT, Borgeson B, Hartland C, et al. Cell painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes. Nat Protoc. 2016;11:1757\u201374.","journal-title":"Nat Protoc"},{"key":"3047_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109318","volume":"36","author":"Y German","year":"2021","unstructured":"German Y, Vulliard L, Kamnev A, Pfajfer L, Huemer J, Mautner AK, et al. Morphological profiling of human T and NK lymphocytes by high-content cell imaging. Cell Rep. 2021;36. 109318.","journal-title":"Cell Rep"},{"key":"3047_CR32","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1038\/s41596-023-00840-9","volume":"18","author":"BA Cimini","year":"2023","unstructured":"Cimini BA, Chandrasekaran SN, Kost-Alimova M, Miller L, Goodale A, Fritchman B, et al. Optimizing the cell painting assay for image-based profiling. Nat Protoc. 2023;18:1981\u20132013.","journal-title":"Nat Protoc"},{"key":"3047_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-61547-x","volume":"16","author":"M Tegtmeyer","year":"2025","unstructured":"Tegtmeyer M, Liyanage D, Han Y, Hebert KB, Pei R, Way GP, et al. Combining phenomics with transcriptomics reveals cell-type-specific morphological and molecular signatures of the 22q11.2 deletion. Nat Commun. 2025;16. 6332.","journal-title":"Nat Commun"},{"key":"3047_CR34","doi-asserted-by":"crossref","unstructured":"Vonficht D, Jopp-Saile L, Yousefian S, Flore V, Sim\u00f3 Vesperinas I, Teuber R, et al. Ultra-high-scale cytometry-based cellular interaction mapping. Nat Methods. 2025;22:1887\u201399.","DOI":"10.1038\/s41592-025-02744-w"},{"key":"3047_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349.","journal-title":"N Engl J Med"},{"key":"3047_CR36","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/ni.2538","volume":"14","author":"CS Guy","year":"2013","unstructured":"Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, Smeltzer M, et al. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol. 2013;14:262\u201370.","journal-title":"Nat Immunol"},{"key":"3047_CR37","doi-asserted-by":"publisher","first-page":"22128","DOI":"10.1073\/pnas.1016388108","volume":"107","author":"IA Yudushkin","year":"2010","unstructured":"Yudushkin IA, Vale RD. Imaging T-cell receptor activation reveals accumulation of tyrosine-phosphorylated CD3\u03b6 in the endosomal compartment. Proc Natl Acad Sci USA. 2010;107:22128\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3047_CR38","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ni951","volume":"4","author":"JB Huppa","year":"2003","unstructured":"Huppa JB, Gleimer M, Sumen C, Davis MM. Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol. 2003;4:749\u201355.","journal-title":"Nat Immunol"},{"key":"3047_CR39","doi-asserted-by":"crossref","unstructured":"Evnouchidou I, Chappert P, Benadda S, Zucchetti A, Weimershaus M, Bens M, et al. IRAP-dependent endosomal T cell receptor signalling is essential for T cell responses. Nat Commun. 2020;2.","DOI":"10.1038\/s41467-020-16471-7"},{"key":"3047_CR40","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S1074-7613(00)00066-2","volume":"13","author":"H Liu","year":"2000","unstructured":"Liu H, Rhodes M, Wiest DL, Vignali DAA. On the dynamics of TCR: CD3 complex cell surface expression and downmodulation. Immunity. 2000;13:665\u201375.","journal-title":"Immunity"},{"key":"3047_CR41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/s41586-022-05028-x","volume":"608","author":"J Shilts","year":"2022","unstructured":"Shilts J, Severin Y, Galaway F, M\u00fcller-Sienerth N, Chong ZS, Pritchard S, et al. A physical wiring diagram for the human immune system. Nature. 2022;608:397\u2013404.","journal-title":"Nature"},{"key":"3047_CR42","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/nchembio.2360","volume":"13","author":"GI Vladimer","year":"2017","unstructured":"Vladimer GI, Snijder B, Krall N, Bigenzahn JW, Huber KVM, Lardeau CH, et al. Global survey of the immunomodulatory potential of common drugs. Nat Chem Biol. 2017;13:681\u201390.","journal-title":"Nat Chem Biol"},{"key":"3047_CR43","doi-asserted-by":"publisher","DOI":"10.1172\/jci35017","author":"AG Ramsay","year":"2008","unstructured":"Ramsay AG, Johnson AJ, Lee AM, Gorg\u00fcn G, Le Dieu R, Blum W, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. J Clin Investig. 2008.","journal-title":"J Clin Investig"},{"key":"3047_CR44","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1182\/bloodadvances.2022007625","volume":"7","author":"S Girgis","year":"2023","unstructured":"Girgis S, Wang Lin SX, Pillarisetti K, Verona R, Vieyra D, Casneuf T, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma. Blood Adv. 2023;7:644\u20138.","journal-title":"Blood Adv"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03047-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03047-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T19:01:40Z","timestamp":1787684500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03047-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3047"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03047-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"12 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SRB and JK are on the pharmaceutical advisory board of Johnson and Johnson.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}